Barclays Upgrades GlaxoSmithKline (GSK) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $50.02 --0%
Rating Summary:
8 Buy, 14 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 2 | Down: 2 | New: 31
Rating Summary:
8 Buy, 14 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 2 | Down: 2 | New: 31
Join SI Premium – FREE
Barclays upgraded GlaxoSmithKline (NYSE: GSK) from Equalweight to Overweight.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $44.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves GSK's Hibsago for chronic hepatitis B treatment
- Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer
- Deutsche Bank Upgrades EssilorLuxottica SA (EL:FP) (ESLOY) to Buy
Create E-mail Alert Related Categories
UpgradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
